Design and characterization of controlled release formulation of Mesna by using different polymers

Padhy Aniket, Gopi G, P. Pk
{"title":"Design and characterization of controlled release formulation of Mesna by using different polymers","authors":"Padhy Aniket, Gopi G, P. Pk","doi":"10.26452/fjphs.v4i3.643","DOIUrl":null,"url":null,"abstract":"The current study created a controlled-release formulation of Mesna to keep the drug at therapeutic levels for longer than ten hours. Eudragit L 100, Chitosan, HPMC K4M. The dose of mesna was set at 100 mg. The tablet's total weight was calculated to be 100 mg. Polymers were employed in concentrations of 50 mg, 100 mg, and 150 mg. Every formulation passed several physicochemical evaluation criteria and was determined to be within tolerances. However, it was clear from the dissolving trials that the formulation (F6) had a better and more desirable drug release pattern, achieving 96.47% in 10 hours. As a controlled release substance, it contains the naturally occurring polymer Mesna. The release kinetics mechanism was in zero order. The optimal formulation was used again for reproducibility, and conformance was tested in all quality control procedures. It was discovered that the outcomes were very impossible for one another. The optimized formula will be used for formulation development and other studies, such as bio-equivalency research, to ensure a successful product launch.","PeriodicalId":12614,"journal":{"name":"Future Journal of Pharmaceuticals and Health Sciences","volume":"6 2","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future Journal of Pharmaceuticals and Health Sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.26452/fjphs.v4i3.643","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

The current study created a controlled-release formulation of Mesna to keep the drug at therapeutic levels for longer than ten hours. Eudragit L 100, Chitosan, HPMC K4M. The dose of mesna was set at 100 mg. The tablet's total weight was calculated to be 100 mg. Polymers were employed in concentrations of 50 mg, 100 mg, and 150 mg. Every formulation passed several physicochemical evaluation criteria and was determined to be within tolerances. However, it was clear from the dissolving trials that the formulation (F6) had a better and more desirable drug release pattern, achieving 96.47% in 10 hours. As a controlled release substance, it contains the naturally occurring polymer Mesna. The release kinetics mechanism was in zero order. The optimal formulation was used again for reproducibility, and conformance was tested in all quality control procedures. It was discovered that the outcomes were very impossible for one another. The optimized formula will be used for formulation development and other studies, such as bio-equivalency research, to ensure a successful product launch.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
使用不同聚合物设计和表征 Mesna 的控释制剂
目前的研究创建了一种 Mesna 的控释制剂,可将药物保持在治疗水平长达十多个小时。Eudragit L 100、壳聚糖、HPMC K4M。美司那的剂量设定为 100 毫克。计算得出片剂的总重量为 100 毫克。聚合物的浓度分别为 50 毫克、100 毫克和 150 毫克。每个制剂都通过了多项理化评估标准,并被确定在容许范围内。不过,从溶解试验中可以明显看出,配方(F6)的药物释放模式更好、更理想,在 10 小时内达到 96.47%。作为一种控释物质,它含有天然聚合物 Mesna。释放动力学机制为零阶。再次使用最佳配方进行重现性试验,并对所有质量控制程序的一致性进行测试。结果发现,两者之间的结果很不可能一致。优化配方将用于配方开发和其他研究,如生物等效性研究,以确保产品成功上市。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Design and characterization of controlled release formulation of Mesna by using different polymers Deciphering the role and impact of India's pharmaceutical industries and its regulatory compliance Formulation and evaluation of Metoprolol succinate buccal tablets in hypertension treatment Formulation and evaluation of amoxapine mucoadhesive buccal films Significance of Alternative Medicines in Treatment of Chronic Diseases: A Comprehensive Review
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1